JP7439059B2 - 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 - Google Patents
光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 Download PDFInfo
- Publication number
- JP7439059B2 JP7439059B2 JP2021514255A JP2021514255A JP7439059B2 JP 7439059 B2 JP7439059 B2 JP 7439059B2 JP 2021514255 A JP2021514255 A JP 2021514255A JP 2021514255 A JP2021514255 A JP 2021514255A JP 7439059 B2 JP7439059 B2 JP 7439059B2
- Authority
- JP
- Japan
- Prior art keywords
- macrophages
- photoaging
- skin
- pigmentation
- dermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010051246 Photodermatosis Diseases 0.000 title claims description 112
- 230000019612 pigmentation Effects 0.000 title claims description 112
- 238000000034 method Methods 0.000 title claims description 75
- 230000008845 photoaging Effects 0.000 title claims description 70
- 230000002500 effect on skin Effects 0.000 title claims description 66
- 239000002537 cosmetic Substances 0.000 title claims description 39
- 239000003112 inhibitor Substances 0.000 title claims description 25
- 238000011156 evaluation Methods 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title description 31
- 238000012216 screening Methods 0.000 title description 16
- 210000003491 skin Anatomy 0.000 claims description 187
- 210000004322 M2 macrophage Anatomy 0.000 claims description 92
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 87
- 239000000284 extract Substances 0.000 claims description 68
- 230000000638 stimulation Effects 0.000 claims description 63
- 239000003814 drug Substances 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 240000002657 Thymus vulgaris Species 0.000 claims description 24
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 23
- 244000141009 Hypericum perforatum Species 0.000 claims description 22
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 22
- 239000001585 thymus vulgaris Substances 0.000 claims description 22
- 238000004364 calculation method Methods 0.000 claims description 18
- 230000003796 beauty Effects 0.000 claims description 16
- 210000002615 epidermis Anatomy 0.000 claims description 14
- 229940007062 eucalyptus extract Drugs 0.000 claims description 14
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 13
- 229960000401 tranexamic acid Drugs 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 12
- 238000003825 pressing Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 241000228212 Aspergillus Species 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 77
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 62
- 210000002950 fibroblast Anatomy 0.000 description 56
- 210000002540 macrophage Anatomy 0.000 description 47
- 239000006228 supernatant Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 31
- 108010035532 Collagen Proteins 0.000 description 25
- 102000008186 Collagen Human genes 0.000 description 25
- 229920001436 collagen Polymers 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 108020004999 messenger RNA Proteins 0.000 description 21
- 108010005774 beta-Galactosidase Proteins 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 210000004207 dermis Anatomy 0.000 description 16
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 description 13
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 12
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000032683 aging Effects 0.000 description 11
- 230000037319 collagen production Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 108010050808 Procollagen Proteins 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000001000 micrograph Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 241000219927 Eucalyptus Species 0.000 description 8
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 8
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 8
- 102100022338 Integrin alpha-M Human genes 0.000 description 8
- 102100025136 Macrosialin Human genes 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- -1 IPMCs Polymers 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000003953 foreskin Anatomy 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000004129 EU approved improving agent Substances 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000012137 double-staining Methods 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000009758 senescence Effects 0.000 description 4
- 102000003780 Clusterin Human genes 0.000 description 3
- 108090000197 Clusterin Proteins 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 240000006001 Thymus serpyllum Species 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000011382 collagen catabolic process Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710100366 A disintegrin and metalloproteinase with thrombospondin motifs 2 Proteins 0.000 description 2
- 102100027400 A disintegrin and metalloproteinase with thrombospondin motifs 4 Human genes 0.000 description 2
- 101100055072 Agrocybe aegerita Agr1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 2
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000972673 Phellodendron amurense Species 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 102100027287 Serpin H1 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 235000005158 Thymus praecox ssp. arcticus Nutrition 0.000 description 2
- 235000004054 Thymus serpyllum Nutrition 0.000 description 2
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000344765 Aspergillus elegans Species 0.000 description 1
- AVWTXYWHGFHGQD-ZKCHVHJHSA-N CNC(=O)[C@H]1CC[C@H](CN)CC1 Chemical compound CNC(=O)[C@H]1CC[C@H](CN)CC1 AVWTXYWHGFHGQD-ZKCHVHJHSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 229920002595 Dielectric elastomer Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 229940122588 Heparanase inhibitor Drugs 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 1
- 101000925493 Homo sapiens Endothelin-1 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 241000782597 Hypericum erectum Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001079007 Phellodendron chinense Species 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- 241000872198 Serjania polyphylla Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003540 anti-differentiation Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001440 melanophage Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/42—Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023212456A JP2024037928A (ja) | 2019-04-19 | 2023-12-15 | 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019080490 | 2019-04-19 | ||
| JP2019080490 | 2019-04-19 | ||
| JP2019108944 | 2019-06-11 | ||
| JP2019108944 | 2019-06-11 | ||
| JP2019158985 | 2019-08-30 | ||
| JP2019158985 | 2019-08-30 | ||
| PCT/JP2020/017082 WO2020213743A1 (ja) | 2019-04-19 | 2020-04-20 | 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212456A Division JP2024037928A (ja) | 2019-04-19 | 2023-12-15 | 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020213743A1 JPWO2020213743A1 (zh) | 2020-10-22 |
| JPWO2020213743A5 JPWO2020213743A5 (zh) | 2023-03-01 |
| JP7439059B2 true JP7439059B2 (ja) | 2024-02-27 |
Family
ID=72837371
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514255A Active JP7439059B2 (ja) | 2019-04-19 | 2020-04-20 | 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 |
| JP2023212456A Pending JP2024037928A (ja) | 2019-04-19 | 2023-12-15 | 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212456A Pending JP2024037928A (ja) | 2019-04-19 | 2023-12-15 | 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 |
Country Status (3)
| Country | Link |
|---|---|
| JP (2) | JP7439059B2 (zh) |
| CN (2) | CN113784753A (zh) |
| WO (1) | WO2020213743A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118043048A (zh) * | 2021-10-14 | 2024-05-14 | 株式会社资生堂 | M2或m2样巨噬细胞的诱导或激活剂、m2或m2样巨噬细胞的诱导或激活方法、用于预防和/或改善真皮的色素沉积的组合物、以及预防和/或改善真皮的色素沉积的方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009268640A (ja) | 2008-05-02 | 2009-11-19 | Kao Corp | 皮膚内部の弾性計測方法 |
| JP2012229924A (ja) | 2011-04-25 | 2012-11-22 | Shiseido Co Ltd | 過酸化脂質の定量分析方法 |
| JP2013083504A (ja) | 2011-10-07 | 2013-05-09 | Pola Chem Ind Inc | スクリ−ニング方法 |
| JP2014041043A (ja) | 2012-08-22 | 2014-03-06 | Rohto Pharmaceut Co Ltd | 皮膚状態の評価方法 |
| JP2014080386A (ja) | 2012-10-16 | 2014-05-08 | Shiseido Co Ltd | 美白方法及びメラニン合成抑制剤のスクリーニング方法 |
| JP2014215286A (ja) | 2013-04-30 | 2014-11-17 | 株式会社シャネル化粧品技術開発研究所 | メラニン生成又は色素沈着を調節するための候補化合物のスクリーニング方法 |
| JP2017080341A (ja) | 2015-10-30 | 2017-05-18 | 株式会社 資生堂 | 美容装置 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008280271A (ja) * | 2007-05-09 | 2008-11-20 | Oriza Yuka Kk | 皮膚光老化予防剤 |
| CN103505374B (zh) * | 2012-06-20 | 2016-02-10 | 郑锦芬 | 一种抗皮肤光老化制剂及其应用 |
| CN103830118A (zh) * | 2014-03-26 | 2014-06-04 | 清华大学 | 红景天苷在制备预防皮肤光老化护肤品的用途及使用方法 |
| CN105998021B (zh) * | 2016-05-18 | 2019-04-05 | 西安交通大学第一附属医院 | 甲基莲心碱防治皮肤光老化的应用 |
| CN106726695A (zh) * | 2017-02-11 | 2017-05-31 | 佛山市芊茹化妆品有限公司 | 一种抗光老化面贴膜 |
| KR101934793B1 (ko) * | 2017-05-26 | 2019-01-03 | 주식회사 아토큐앤에이 | 고욤나무 잎 추출물을 유효성분으로 함유하는 피부 광노화 예방 또는 개선용 조성물 |
-
2020
- 2020-04-20 CN CN202080029442.2A patent/CN113784753A/zh active Pending
- 2020-04-20 CN CN202410125329.4A patent/CN117815216A/zh active Pending
- 2020-04-20 JP JP2021514255A patent/JP7439059B2/ja active Active
- 2020-04-20 WO PCT/JP2020/017082 patent/WO2020213743A1/ja active Application Filing
-
2023
- 2023-12-15 JP JP2023212456A patent/JP2024037928A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009268640A (ja) | 2008-05-02 | 2009-11-19 | Kao Corp | 皮膚内部の弾性計測方法 |
| JP2012229924A (ja) | 2011-04-25 | 2012-11-22 | Shiseido Co Ltd | 過酸化脂質の定量分析方法 |
| JP2013083504A (ja) | 2011-10-07 | 2013-05-09 | Pola Chem Ind Inc | スクリ−ニング方法 |
| JP2014041043A (ja) | 2012-08-22 | 2014-03-06 | Rohto Pharmaceut Co Ltd | 皮膚状態の評価方法 |
| JP2014080386A (ja) | 2012-10-16 | 2014-05-08 | Shiseido Co Ltd | 美白方法及びメラニン合成抑制剤のスクリーニング方法 |
| JP2014215286A (ja) | 2013-04-30 | 2014-11-17 | 株式会社シャネル化粧品技術開発研究所 | メラニン生成又は色素沈着を調節するための候補化合物のスクリーニング方法 |
| JP2017080341A (ja) | 2015-10-30 | 2017-05-18 | 株式会社 資生堂 | 美容装置 |
Non-Patent Citations (2)
| Title |
|---|
| BECKER L、外5名，Age-dependent Shift in Macrophage Polarisation Causes Inflammation-Mediated Degeneration of Enteric，Gut，2017年，Vol.67,No.5，Page.827-836， doi: 10.1136/gutjnl-2016-312940. Epub 2017 Feb 21. |
| 真鍋 一郎，慢性炎症と加齢関連疾患，日本老年医学会雑誌，日本，2017年，Vol.54,No.2，Page.105-113，https://doi.org/10.3143/geriatrics.54.105 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024037928A (ja) | 2024-03-19 |
| CN113784753A (zh) | 2021-12-10 |
| JPWO2020213743A1 (zh) | 2020-10-22 |
| WO2020213743A1 (ja) | 2020-10-22 |
| CN117815216A (zh) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farage et al. | Characteristics of the aging skin | |
| JP5628797B2 (ja) | 人参の花または人参の種子抽出物を含有する皮膚外用剤組成物 | |
| Sasaki | Micro-needling depth penetration, presence of pigment particles, and fluorescein-stained platelets: clinical usage for aesthetic concerns | |
| Narita et al. | Sequential scalp assessment in hair regeneration therapy using an adipose-derived stem cell–conditioned medium | |
| JP2024037928A (ja) | 光老化及び／又は真皮色素沈着を予防及び／又は改善するための方法，装置，および抗光老化及び／又は真皮色素沈着抑制剤，抗光老化及び／又は真皮色素沈着抑制剤のスクリーニング方法，抗光老化及び／又は真皮色素沈着抑制美容処置の評価方法，並びに光老化及び／又は真皮色素沈着度の評価方法 | |
| Wu et al. | Inhibitory effect of antioxidant peptides derived from Pinctada fucata protein on ultraviolet-induced photoaging in mice | |
| CN110840812A (zh) | 胎体来源的外泌体在皮肤调节产品中的用途 | |
| KR101858095B1 (ko) | 커큐민을 포함하는 강황 추출물을 유효 성분으로 포함하는 피부 미백, 주름 형성 억제, 및 소양증 완화용 화장품 조성물 | |
| Lee et al. | Effect of extracorporeal shock wave therapy for burn scar regeneration: a prospective, randomized, double-blinded study | |
| Abreu et al. | Immunological parameters associated with vitiligo treatments: a literature review based on clinical studies | |
| JP2012528147A (ja) | ヒノキ多糖体を含有する皮膚外用剤組成物 | |
| KR20090029750A (ko) | 잎새버섯 추출물 및 이를 함유하는 피지 산생을 촉진하기 위한 조성물 | |
| WO2021215409A1 (ja) | 光老化及び／又は真皮色素沈着を予防及び／又は改善する剤，それを用いた美容方法，及びその方法に適用するための美容装置 | |
| WO2020213745A1 (ja) | 皮膚抗老化のための方法および装置 | |
| KR101208013B1 (ko) | 참바늘버섯 균사체 추출물을 함유하는 피부 외용제 조성물 | |
| Brown et al. | The color of skin: white diseases of the skin, nails, and mucosa | |
| CN109182264A (zh) | 制备人脂肪干细胞培养液的方法及其在美容用品中的应用 | |
| CN114344289A (zh) | 一种具有抗衰老活性的组合物及其制剂和用途 | |
| WO2021215411A1 (ja) | 皮膚抗老化剤，皮膚抗老化のための美容方法およびその方法に使用するための美容装置 | |
| WO2023063118A1 (ja) | Ｍ２又はｍ２様マクロファージの誘導又は活性化剤、ｍ２又はｍ２様マクロファージの誘導又は活性化方法、真皮の色素沈着を予防及び／又は改善するための組成物、並びに真皮の色素沈着を予防及び／又は改善する方法 | |
| CN111166688A (zh) | 青蒿烯作为保湿抗皱、抗衰老成分在化妆品中的应用 | |
| US20230301890A1 (en) | Compositions comprising urolithins | |
| KR102562755B1 (ko) | 이소플라본 비배당체를 포함하는 화장료 조성물 | |
| Shemshuk et al. | Non-thermal atmospheric-pressure plasma in the anti-age therapy of facial skin | |
| KR102419102B1 (ko) | 사과 유래의 엑소좀을 유효성분으로 포함하는 새로운 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230220 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230411 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230607 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230815 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230822 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231019 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231215 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240206 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240214 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7439059 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |